Your guide to phar­ma Q1 num­bers; Un­pack­ing top 15 R&D gi­ants; Se­cret PhI­II fail­ures; 'Weirdo sci­ence' and meta­science; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

It’s not an easy time to be in biotech, but as the say­ing goes, the in­dus­try has nev­er been for the faint-heart­ed. We have all the news cov­ered — and then some — in this week’s edi­tion, along­side a full slate of sto­ries from End­pointsPhar­ma to all through earn­ings week. Have a rest­ful week­end.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER